Skip to Content
Opening Bell
News
YahooOctober 21, 2026 at 6:43 AM NY6 Days Ago

Amgen and AstraZeneca report Phase III Tezspire data for EoE

The trial evaluated 368 participants aged 12 to 80 years who were permitted to continue stable background therapies.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo

Read at Source